Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Biotechnology

Immunovant

Peter Salzmann

Rebecca Merlina

Sheetal Patel

Claudia Jacobs

Jay S. Stout

William Macias

Lauren Schrier

Mark Levine

Lesa Valentine

Jody Roth

Yan Zheng

Renee Barnett

Julia G. Butchko

Clinical Operations Team

Vice Presidents

Leadership Team

Teams at Immunovant

Clinical Operations Team

Vice Presidents

Leadership Team